Solvonis Therapeutics plc
SVNS.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | -0.03 | -0.10 |
| FCF Yield | -47.82% | -245.68% | -21.38% | -1.11% |
| EV / EBITDA | -1.17 | -0.16 | -4.94 | -25.99 |
| Quality | ||||
| ROIC | -44.84% | -151.31% | -59.18% | -47.96% |
| Gross Margin | 0.00% | -22.83% | -9.41% | 25.11% |
| Cash Conversion Ratio | 0.71 | 0.40 | 0.87 | 0.27 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 38.91% | -7.77% | -12.77% |
| Free Cash Flow Growth | 22.86% | 52.24% | -1,107.06% | -1,600.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.55 | 0.04 | 0.63 | -0.39 |
| Interest Coverage | -21.61 | -1,039.00 | -677.00 | -105.63 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 8.75 | 3.17 | 0.00 |
| Cash Conversion Cycle | 0.00 | -44.24 | 30.19 | -1,800.07 |